Fispemifene

Fispemifene
Clinical data
Other names	HM-101
Identifiers
	IUPAC name 2-(2-(4-((1Z)-4-Chloro-1,2-diphenylbut-1-enyl)phenoxy)ethoxy)ethanol;
CAS Number	341524-89-8;
PubChem CID	9954033;
ChemSpider	8129643;
UNII	3VZ2833V08;
KEGG	D10008;
ChEMBL	ChEMBL2107341;
CompTox Dashboard (EPA)	DTXSID90870330 ;
Chemical and physical data
Formula	C26H27ClO3
Molar mass	422.95 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCOCCO)/CCCl;
	InChI InChI=1S/C26H27ClO3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28H,15-20H2/b26-25-; Key:NKZTZAQIKKGTDB-QPLCGJKRSA-N;

Chemical compound

Pharmaceutical compound

Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.^[1]^[2]^[3] It reached phase II clinical trials for this indication before development was terminated in March 2016.^[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.^[1]

References

^ a b c "Fispemifene". AdisInsight. Springer Nature Switzerland AG.
^ Cano A, Calaf i Alsina J, Duenas-Diez JL (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 52–. ISBN 978-3-540-34742-2.
^ Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 90–. ISBN 978-3-527-62330-3.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.